Who Paid My Doc
Dane Dougherty
Rheumatology Springfield, OR Medical Doctor
NPI 1518251370 CMS profile 295905
1007 Harlow Rd Ste 210, Springfield, OR 97477
General payments
$2,209
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Dane Dougherty of Springfield, OR is reported in the CMS Open Payments database as having received $2,209 across 143 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 48th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $123 | 1 | |
| 2022 | General | $13 | 1 | |
| 2021 | General | $13 | 1 | |
| 2020 | General | $52 | 3 | |
| 2019 | General | $2,008 | 137 |
Beside peers
- Dane Dougherty
- Rheumatology median
- Middle half of Rheumatology
- National median
In program year 2025, general payments to Dane Dougherty were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.
Show as a table
| Year | Dane Dougherty | Rheumatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,008 | $744 | $153–$2,687 | $163 |
| 2020 | $52 | $462 | $98–$2,027 | $114 |
| 2021 | $13 | $531 | $101–$2,153 | $132 |
| 2022 | $13 | $627 | $125–$2,303 | $149 |
| 2023 | $123 | $741 | $145–$2,524 | $160 |
| 2024 | $0 | $830 | $166–$2,660 | $164 |
| 2025 | $0 | $903 | $171–$2,775 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 53 drugsPart D claims
3,553
Drug cost
$3,618,613
Branded share of claims
27.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Humira(Cf) Pen Adalimumab | Brand | 138 | $1,380,735 | |
| Enbrel Sureclick Etanercept | Brand | 57 | $441,623 | |
| Cosentyx Sensoready (2 Pens) Secukinumab | Brand | 46 | $406,883 | |
| Xeljanz Xr Tofacitinib Citrate | Brand | 49 | $291,568 | |
| Cosentyx Sensoready Pen Secukinumab | Brand | 20 | $186,152 | |
| Enbrel Etanercept | Brand | 25 | $179,258 | |
| Cosentyx (2 Syringes) Secukinumab | Brand | 21 | $159,735 | |
| Rinvoq Upadacitinib | Brand | 23 | $146,662 | |
| Nucala Mepolizumab | Brand | 13 | $137,247 | |
| Taltz Autoinjector Ixekizumab | Brand | 12 | $91,501 |
The 10 drugs with the highest cost, of 53 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 74 billing codesPaid by Medicare
$848,504
Medicare patients
472
Services billed
72,711
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 62% | |
| Osteoporosis | 48% | |
| Depression | 27% | |
| Diabetes | 19% | |
| Chronic kidney disease | 19% | |
| Ischemic heart disease | 13% | |
| Atrial fibrillation | 13% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, denosumab, 1 mg J0897 | Office | 91 | 7,020 | $141,003 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 | Office | 11 | 3,025 | $102,126 |
| Injection, infliximab, excludes biosimilar, 10 mg J1745 | Office | 20 | 2,890 | $71,874 |
| Injection, golimumab, 1 mg, for intravenous use J1602 | Office | 11 | 7,113 | $57,405 |
| Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg Q5103 | Office | 14 | 2,420 | $22,976 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) Q0138 | Office | 14 | 8,163 | $2,062 |
| Vaccine for influenza for injection into muscle 90653 | Office | 22 | 22 | $1,800 |
| Injection, zoledronic acid, 1 mg J3489 | Office | 38 | 186 | $843 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 54 | 347 | $251 |
| Injection, methylprednisolone sodium succinate, 5 mg J2919 | Office | 12 | 210 | $49 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
143 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Rheumatology in Oregon
Practitioners in the same specialty and state, ranked by reported value.
All Rheumatology
Everyone recorded under this specialty, nationwide.
Doctors in Oregon
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.